Company News

"Is Now the Time to Build in China?" – Bluestar Publishes Article Analyzing China Pharmaceutical Market Entry Strategies

The Bluestar team has been assisting US companies interested in learning about the evolving pharmaceutical market in China, and advising on cross-border business development initiatives. We have distilled key observations from recent market trends and written an in-depth paper on the topic of “build” vs. “rent” in China. It is published in the Oct 7, 2021 issue of In Vivo, an Informa Pharma Intelligence publication.

Paul Zhang Hosts China Innovative Pharma Panel at the 2021 China Focus Conference

On January 10, 2021, Paul Zhang, Partner at Bluestar BioAdvisors LLC hosted a panel discussion titled “The Dawn of Innovative Pharmaceutical Market in China” during the annual China Focus conference, which took place simultaneously with the 39th virtual JP Morgan Healthcare Conference. Paul was joined by the following senior leaders of four innovative Chinese biotechnology companies ...

Paul Zhang Hosts U.S./China Licensing Due Diligence Panel at the 2020 LES Annual Conference

On October 20, 2020, Paul Zhang, Partner at Bluestar BioAdvisors LLC hosted a panel discussion titled “Due Diligence Best Practices: U.S./China Cross-Border Licensing Agreements” during the North American Licensing Executives Society (LES)’s annual meeting. Paul was joined by an all-star cast of panelists ...

Paul Zhang Serves as a China Expert at SVB Leerink’s Affordable Medicines Forum

On October 16, 2020, Paul Zhang, Partner at Bluestar BioAdvisors LLC was an expert guest in a virtual “fireside chat” titled “China Market: Promises & Misconceptions”, hosted by SVB Leerink biotechnology analyst Ami Fadia during the Affordable Medicines Forum for investors ...

Monika Trzcinska participates in life sciences consulting panel at Harvard GSAS Consulting Club

On April 16, 2020, Monika Trzcinska, Partner at Bluestar BioAdvisors, LLC (Bluestar) joined the Life Sciences Consulting panel hosted by the Harvard GSAS Club, a student organization that provides educational programs and helps to bridge the gap between industry and academia ...

Monika Trzcinska participates in Women in Consulting Panel at Harvard GSAS Consulting Club; Paul Zhang serves as a judge in the annual case competition at Yale Graduate Consulting Club

On March 19, 2020, Monika Trzcinska, Partner at Bluestar BioAdvisors, LLC (Bluestar) joined the Women in Consulting panel hosted by the Harvard GSAS Club ... On March 20, 2020, Paul Zhang, Partner at Bluestar, joined the annual case competition hosted by the Yale Graduate Consulting Club (YGCC) ...

Paul Zhang moderates panel discussion during JPM Week 2020

Paul Zhang, Partner at Bluestar BioAdvisors LLC, led a panel discussion at the China Focus Forum on January 12 in San Francisco, leading up to the JP Morgan Healthcare conference 2020 ...

Bluestar BioAdvisors welcomes Erin Olsen as Managing Director

Bluestar BioAdvisors announced today that Erin Olsen has been named as a Managing Director of the firm. She joins Darren Eskow, Monika Trzcinska, and Paul Zhang as part of the Bluestar leadership team ...

Bluestar BioAdvisors welcomes Paul Zhang as Partner

Bluestar BioAdvisors announced today that Paul Zhang has been named as a Partner of the firm. He joins Darren Eskow and Monika Trzcinska as the Operating Partners of Bluestar ...

The consulting business of Torreya Insights spins out into a new entity - Bluestar BioAdvisors, LLC

The consulting team from Torreya Insights has spun out into a new entity called Bluestar BioAdvisors, LLC. (“Bluestar”). A boutique, client-centered consulting firm specializing in the life sciences industry, Bluestar will be led by co-founders and Managing Directors ...

Bluestar Pulses

Pulses are our e-newsletters that look at recent trends and promising directions across life sciences. Add your name to our mail list to receive future updates.

Past Issues

Oncology Pulse | Jan. 2024

New Oncology Agents – A Look Back and the Year Ahead

Follow-on targeted therapies and T-cell engagers for liquid tumors accounted for most of the new oncology agents last year; 18 drugs and 9 MOAs are already filed for this year, with cell therapies and a T-cell engager for solid tumors and a new ADC target on the list of potential approvals.

View Issue »
Download PDF »

Gene Therapy Pulse | Dec. 2023

Outlook on Gene Therapy

The cell and gene therapy space has seen significant growth in the last five years and continues to rapidly evolve. Realization of future potential faces key technical, clinical, and commerical challenges.

View Issue »
Download PDF »

Oncology Pulse | Nov. 2023

Challengers to Auto CAR-T in Liquid Tumors, namely bispecific T-cell engagers and allogeneic CAR-T, are emerging.

For now, auto CAR-T is prioritized over bispecifics due to longer term data, but both approaches are seeking to push into earlier lines and allogeneic CAR-Ts are aiming to provide the efficacy of CAR-T with an off-the-shelf product.

View Issue »
Download PDF »

Oncology Pulse | Sept. 2023

Overcoming checkpoint inhibitor (CPI) resistance has been a major area of investigation with few successes so far.

Segmenting PD-(L)1 rechallenge patients by type of resistance could be a path to success — and assumptions for efficacy post-CPI may need to be increased.

View Issue »
Download PDF »

Oncology Pulse | May 2023

The inaugural issue categorizes FDA approvals for oncology therapies over the past five years and notes programs to watch in 2023.

Targeted therapies have accounted for the majority of new oncology drugs over the past five years, but a more diverse set of approaches are being approved; IRA and accelerated approval changes also portend changes.

View Issue »
Download PDF »